Is the PolyNovo share price in the buy zone?

The PolyNovo Ltd (ASX: PNV) share price closed yesterday's trading session more than 8% higher and could be in the buy zone for 2020.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The PolyNovo Ltd (ASX: PNV) share price closed yesterday's trading session more than 8% higher. Although there was no direct catalyst to prompt the share price move, it could be an indication of continued interest in the company.

What does PolyNovo do?

PolyNovo is an Australian-based medical technology company that designs, develops and manufactures dermal regeneration solutions. The company is based around CSIRO medical technology developed following the Bali bombings as an alternative to animal-based products.

PolyNovo's flagship NovoSorb Biodegradeable Temporising Matrix (BTM) product is a biodegradable polyurethane-based polymer that helps the body use its own systems to repair damaged tissue. NovoSorb acts as a dermal scaffold and is then broken down into carbon dioxide and lactic acid, which is excreted through urine. NovoSorb's cutting-edge technology was displayed recently during theWhite Island volcano tragedy in New Zealand.  

NovoSorb is currently marketed in Australia, New Zealand and the US, with PolyNovo recently obtaining licencing approval for the UK and the European Union.

How did PolyNovo perform in 2019?

The PolyNovo share price surged in 2019, closing more than 230% higher for the year and hitting all-time highs. PolyNovo also reported strong full-year earnings for FY19, with the company reporting a revenue increase of 128% from the previous year of $13.68 million. Revenue growth was fuelled by a 435% increase in sales revenue of NovoSorb, which clocked in at $9.3 million for the year.  

PolyNovo was awarded for its stellar performance with the company being an addition to the S&P/ASX 200 (INDEXASX: XJO) in the September quarterly rebalance. Inclusion in the ASX 200 opens additional avenues of growth for the PolyNovo share price as index funds look to get involved.

Should you buy?

I don't usually advocate buying shares in a company that has experienced a meteoric rise like PolyNovo. However, the growth prospects are tremendous for the company. PolyNovo is well positioned in key markets, especially the US with rapid expansion of its sales team. In addition, licencing approval for access to addressable markets in the UK and European Union offers excellent growth potential. This potential was reflected at the PolyNovo AGM late last year, when the company's management informed shareholders that its was on track to double sales revenue for NovoSorb in FY20.

PolyNovo's addition to the ASX 200 provides the company with favourable exposure to index funds and larger institutional investors. The company is also in the process of developing a variety of products that address hernia's, breast reconstruction and various other skin technologies.

I think that PolyNovo is an exciting company with excellent growth prospects. A prudent strategy would be to keep PolyNovo on a watchlist and wait for positive price action before making an investment decision.

Another ASX-listed skin specialist to add to your watchlist is Avita Medical Limited (ASX: AVH), which was co-founded by plastic surgeon and former Australian of the Year, Dr Fiona Wood AM, who is also director of the Royal Perth Hospital burns unit and the Western Australia Burns Service.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Morgans names 3 ASX stocks to buy

The broker is feeling very positive on the investment opportunities here.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Share Market News

3 of the best ASX shares to buy with $5,000

These shares could be among the best to buy now according to Bell Potter.

Read more »

A woman holds her finger to the side of her lips in contemplation as she looks upwards to an array of graphic images of light bulbs above her head, one of which is on and glowing.
Share Market News

Macquarie tips more than 15% upside for this ASX 200 utilities stock

This ASX 200 stock could be set to rise.

Read more »

A woman stands at her desk looking a her phone with a panoramic view of the harbour bridge in the windows behind her with work colleagues in the background.
Share Market News

5 things to watch on the ASX 200 on Friday

Will the market end the week strongly? Let's find out.

Read more »

A businessman stacks building blocks.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares hit a new record high today.

Read more »

A man sees some good news on his phone and gives a little cheer.
Share Gainers

Why Auckland Airport, Australian Ethical, Breville, and Clarity shares are charging higher

These shares are having a better day than most on Thursday. But why?

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why 29Metals, CAR Group, DroneShield, and Santana Minerals shares are falling today

These shares are missing out on the good times on Thursday. But why?

Read more »